BIOS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIOS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. BioPlus Acquisition's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. BioPlus Acquisition's Total Assets for the quarter that ended in Jun. 2023 was $189.73 Mil. Therefore, BioPlus Acquisition's Asset Turnover for the quarter that ended in Jun. 2023 was 0.00.
Asset Turnover is linked to ROE % through Du Pont Formula. BioPlus Acquisition's annualized ROE % for the quarter that ended in Jun. 2023 was 2.86%. It is also linked to ROA % through Du Pont Formula. BioPlus Acquisition's annualized ROA % for the quarter that ended in Jun. 2023 was 2.62%.
The historical data trend for BioPlus Acquisition's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPlus Acquisition Annual Data | |||||
Trend | Dec21 | Dec22 | |||
Asset Turnover | - | - |
BioPlus Acquisition Quarterly Data | ||||||||||
Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Asset Turnover | Get a 7-Day Free Trial | - | - | - | - | - |
For the Shell Companies subindustry, BioPlus Acquisition's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's Asset Turnover distribution charts can be found below:
* The bar in red indicates where BioPlus Acquisition's Asset Turnover falls into.
Asset Turnover measures how quickly a company turns over its asset through sales.
BioPlus Acquisition's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (A: Dec. 2022 ) | / | ( (Total Assets (A: Dec. 2021 ) | + | Total Assets (A: Dec. 2022 )) | / count ) |
= | 0 | / | ( (235.981 | + | 238.325) | / 2 ) |
= | 0 | / | 237.153 | |||
= | 0.00 |
BioPlus Acquisition's Asset Turnover for the quarter that ended in Jun. 2023 is calculated as
Asset Turnover | ||||||
= | Revenue | / | Average Total Assets | |||
= | Revenue (Q: Jun. 2023 ) | / | ( (Total Assets (Q: Mar. 2023 ) | + | Total Assets (Q: Jun. 2023 )) | / count ) |
= | 0 | / | ( (240.82 | + | 138.63) | / 2 ) |
= | 0 | / | 189.725 | |||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
BioPlus Acquisition (NAS:BIOS) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
BioPlus Acquisition's annulized ROE % for the quarter that ended in Jun. 2023 is
ROE %** | (Q: Jun. 2023 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | 4.964 | / | 173.585 | ||
= | (Net Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (4.964 / 0) | * | (0 / 189.725) | * | (189.725/ 173.585) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | % | * | 0 | * | 1.093 |
= | ROA % | * | Equity Multiplier | ||
= | 2.62 % | * | 1.093 | ||
= | 2.86 % |
Note: The Net Income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
BioPlus Acquisition's annulized ROA % for the quarter that ended in Jun. 2023 is
ROA % | (Q: Jun. 2023 ) | ||
= | Net Income | / | Total Assets |
= | 4.964 | / | 189.725 |
= | (Net Income / Revenue) | * | (Revenue / Total Assets) |
= | (4.964 / 0) | * | (0 / 189.725) |
= | Net Margin % | * | Asset Turnover |
= | % | * | 0 |
= | 2.62 % |
Note: The Net Income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Thank you for viewing the detailed overview of BioPlus Acquisition's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
Steven C. Fletcher | 10 percent owner | C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807 |
Explorer Parent Llc | 10 percent owner | 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012 |
Founder Holdings Llc | 10 percent owner | 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012 |
Alex Serge Vieux | 10 percent owner | C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749 |
Bioplus Sponsor Llc | 10 percent owner | 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010 |
Stephen A Sherwin | director | C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080 |
Louis G Lange | director | 3172 PORTER DRIVE, PALO ALTO CA 94034 |
Ross Haghighat | director, officer: CEO and CFO | C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710 |
Ronald W Eastman | director | 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301 |
Shawn Cross | director | 1825 K STREET SUITE 510, WASHINGTON DC 20006 |
Jonathan Rigby | director, officer: Chief Business Officer | ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545 |
Glen Giovannetti | director | UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000 |
From GuruFocus
By Marketwired • 08-16-2023
By sperokesalga sperokesalga • 06-13-2023
By Marketwired • 10-04-2023
By Marketwired • 07-17-2023
By sperokesalga sperokesalga • 05-03-2023
By Marketwired • 10-04-2023
By GuruFocusNews GuruFocusNews • 12-06-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.